MA38217B1 - Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2 - Google Patents

Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2

Info

Publication number
MA38217B1
MA38217B1 MA38217A MA38217A MA38217B1 MA 38217 B1 MA38217 B1 MA 38217B1 MA 38217 A MA38217 A MA 38217A MA 38217 A MA38217 A MA 38217A MA 38217 B1 MA38217 B1 MA 38217B1
Authority
MA
Morocco
Prior art keywords
receptor agonists
pyrazine derivatives
new pyrazine
new
compound
Prior art date
Application number
MA38217A
Other languages
English (en)
Other versions
MA38217A1 (fr
Inventor
Uwe Grether
Matthias Nettekoven
Stephan Roever
Baledi Dhurwasulu
Mark Rogers-Evans
Tanja Schulz-Gasch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA38217A1 publication Critical patent/MA38217A1/fr
Publication of MA38217B1 publication Critical patent/MA38217B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé de formule (i) où r1 à r4 sont tels que définis dans la description et les revendications. Le composé de formule (i) est un agoniste des récepteurs cb2 destiné à être utilisé dans le traitement de plusieurs troubles, comme la douleur, l'athérosclérose et le glaucome.
MA38217A 2012-12-07 2013-12-04 Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2 MA38217B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12196024 2012-12-07
PCT/EP2013/075444 WO2014086807A1 (fr) 2012-12-07 2013-12-04 Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2

Publications (2)

Publication Number Publication Date
MA38217A1 MA38217A1 (fr) 2017-02-28
MA38217B1 true MA38217B1 (fr) 2017-11-30

Family

ID=47290805

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38217A MA38217B1 (fr) 2012-12-07 2013-12-04 Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2

Country Status (33)

Country Link
US (1) US9512141B2 (fr)
EP (1) EP2928882B1 (fr)
JP (1) JP6322646B2 (fr)
KR (1) KR20150092156A (fr)
CN (1) CN104837830B (fr)
AR (1) AR093804A1 (fr)
AU (1) AU2013354115B2 (fr)
BR (1) BR112015009603A2 (fr)
CA (1) CA2885418A1 (fr)
CL (1) CL2015001318A1 (fr)
CR (1) CR20150210A (fr)
CY (1) CY1118808T1 (fr)
DK (1) DK2928882T3 (fr)
EA (1) EA025840B1 (fr)
ES (1) ES2621958T3 (fr)
HK (1) HK1208030A1 (fr)
HR (1) HRP20170572T1 (fr)
HU (1) HUE030836T2 (fr)
IL (1) IL237982A (fr)
IN (1) IN2015DN03145A (fr)
LT (1) LT2928882T (fr)
MA (1) MA38217B1 (fr)
MX (1) MX2015006036A (fr)
PE (1) PE20151060A1 (fr)
PH (1) PH12015501072A1 (fr)
PL (1) PL2928882T3 (fr)
PT (1) PT2928882T (fr)
RS (1) RS55951B1 (fr)
SG (1) SG11201504011UA (fr)
SI (1) SI2928882T1 (fr)
TW (1) TW201427960A (fr)
UA (1) UA116894C2 (fr)
WO (1) WO2014086807A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38403A1 (fr) 2013-03-07 2017-11-30 Hoffmann La Roche Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
PL2978755T3 (pl) 2013-03-26 2018-05-30 Hoffmann La Roche Nowe pochodne pirydyny
CA2907691A1 (fr) 2013-05-02 2014-11-06 F. Hoffmann-La Roche Ag Derives de pyrrolo[2,3-d]pyrimidine en tant qu'agonistes du recepteur cb2
TR201809417T4 (tr) 2013-05-02 2018-07-23 Hoffmann La Roche Cb2 reseptör agonistleri olarak purin türevleri.
PT3041843T (pt) 2013-09-06 2019-02-26 Hoffmann La Roche Derivados de triazolo[4,5-d]pirimidina como agonistas do recetor cb2
MA39843A (fr) * 2014-04-04 2017-02-08 Hoffmann La Roche Pyridine-2-amides utiles comme agonistes de cb2
BR112018011562B1 (pt) 2015-12-09 2023-05-02 F. Hoffmann-La Roche Ag Novos derivados de fenil
TW201904943A (zh) 2017-06-20 2019-02-01 瑞士商赫孚孟拉羅股份公司 新穎吡啶衍生物
EP3814337A1 (fr) 2018-06-27 2021-05-05 F. Hoffmann-La Roche AG Dérivés de pyridine et de pyrazine en tant qu'agonistes de cannabinoïde 2 préférentiels
JP7445610B2 (ja) 2018-06-27 2024-03-07 エフ． ホフマン－ラ ロシュ アーゲー 医療に有用な新規化合物
WO2020002314A1 (fr) 2018-06-27 2020-01-02 F. Hoffmann-La Roche Ag Ligand du récepteur cannabinoïde 2 radiomarqué
WO2022128050A1 (fr) 2020-12-14 2022-06-23 Symrise Ag Médicament pour lutter contre l'inflammation et la douleur

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
BRPI0717822A2 (pt) * 2006-10-04 2013-11-12 Hoffmann La Roche Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto.
WO2012031817A1 (fr) 2010-09-09 2012-03-15 F. Hoffmann-La Roche Ag Détermination des niveaux de protéine abca1 dans des cellules
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
US9403808B2 (en) * 2011-10-28 2016-08-02 Hoffmann-La Roche Inc. Pyrazine derivatives

Also Published As

Publication number Publication date
DK2928882T3 (en) 2017-02-20
CL2015001318A1 (es) 2015-10-02
SI2928882T1 (sl) 2017-05-31
EA201590827A1 (ru) 2015-09-30
SG11201504011UA (en) 2015-07-30
EP2928882B1 (fr) 2017-01-18
CN104837830A (zh) 2015-08-12
EA025840B1 (ru) 2017-02-28
CR20150210A (es) 2015-05-29
PT2928882T (pt) 2017-03-16
UA116894C2 (uk) 2018-05-25
HK1208030A1 (en) 2016-02-19
LT2928882T (lt) 2017-03-27
AU2013354115A1 (en) 2015-04-09
CY1118808T1 (el) 2018-01-10
HRP20170572T1 (hr) 2017-06-16
IN2015DN03145A (fr) 2015-10-02
HUE030836T2 (en) 2017-06-28
US9512141B2 (en) 2016-12-06
PH12015501072B1 (en) 2015-08-03
PL2928882T3 (pl) 2017-07-31
KR20150092156A (ko) 2015-08-12
ES2621958T3 (es) 2017-07-05
CA2885418A1 (fr) 2014-06-12
WO2014086807A1 (fr) 2014-06-12
PH12015501072A1 (en) 2015-08-03
AU2013354115B2 (en) 2017-10-05
US20150299220A1 (en) 2015-10-22
JP2016505557A (ja) 2016-02-25
AR093804A1 (es) 2015-06-24
MX2015006036A (es) 2015-08-07
RS55951B1 (sr) 2017-09-29
PE20151060A1 (es) 2015-07-25
JP6322646B2 (ja) 2018-05-09
TW201427960A (zh) 2014-07-16
EP2928882A1 (fr) 2015-10-14
MA38217A1 (fr) 2017-02-28
IL237982A (en) 2017-06-29
CN104837830B (zh) 2018-07-20
BR112015009603A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
MA38217A1 (fr) Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2
MA38238B1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
MA40308A1 (fr) Pyridine-2- amides utiles comme agonistes de cb2
MA35663B1 (fr) Dérivés de [1, 2, 3]triazolo [4, 5 -d] pyrimidine comme agonistes des récepteurs aux cannabinoïdes 2
MA38239A1 (fr) Nouveaux dérivés de pyridine
MA41625A (fr) Composés de benzazépine dicarboxamide
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA38826B1 (fr) Nouveaux dérivés de triazolo[4,5-d]pyrimidine
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
MA33032B1 (fr) Pyrimidines condensees
TN2015000547A1 (fr) Composes heteroaromatiques et leur utilisation comme ligands de dopamine d1
MA40955A (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA35061B1 (fr) Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
MA38404A1 (fr) Nouveaux dérivés de pyridine
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA38460A1 (fr) Dérivés de la purine en tant qu'agonistes du récepteur cb2
MA43400B1 (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA32985B1 (fr) Nouveaux microbiocides
MA38679A1 (fr) Modulateurs du récepteur de cxcr7